BRONCUS-B(02216) plans to further acquire 3.85% equity of Valgen Holding Corporation for 55.12 million US dollars.

BRONCUS-B(02216) announced on March 21, 2026 that the buyer, Broncus China Holding Corporation (a wholly-owned subsidiary of the company), and the seller, Max Grand Limited, entered into a share purchase agreement. Under the agreement, the seller conditionally agrees to sell and the buyer conditionally agrees to purchase the target shares of Valgen Holding Corporation (representing 3.85% of the issued share capital of the target company as of the date of this announcement) for a total consideration of 55.1202 million US dollars. The target group is primarily engaged in providing solutions for diseases such as mitral valve regurgitation and tricuspid valve regurgitation. Its products include the mitral valve repair device DragonFly (transvenous approach) and the tricuspid valve repair device DragonFly-TTM. The synergies and potential cooperation between the two parties will not only enhance the competitiveness of their existing products but also establish a closed-loop diagnosis and treatment system covering the entire lifecycle of cardiovascular diseases. With the increasing aging population, the synergistic effect of technology based on heart-lung synergy will provide more efficient and precise diagnosis and treatment solutions for patients with cardiovascular diseases, thereby opening up broader market opportunities for both parties. The company believes that the further acquisition is a rare opportunity for the group to further integrate the diagnosis and treatment of cardiovascular diseases.